Suchergebnisse - Dexamethasone OR corticosteroid

1

Clinical review report : (Novartis Pharmaceuticals Canada Inc.) : indication: asthma maintenance, adultsIndacaterol acetate-glycopyrronium bromide-mometasone furoate (Enerzair Breezhaler)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, January 2021

CADTH common drug review

Version: Final (with redactions).

2

Pharmacoeconomic report : (Novartis Pharmaceuticals Canada Inc.) : indication: asthma maintenance, adultsIndacaterol acetate-glycopyrronium bromide-mometasone furoate (Enerzair Breezhaler)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, January 2021

CADTH common drug review

Version: Final (with redactions).

3

Pharmacoeconomic review report : (Novartis Pharmaceuticals Canada Inc.) : indication : once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older with reversible obstructive airway diseaseIndacaterol/mometasone furoate (Atectura Breezhaler)

Erschienen: Ottawa, Canadian Agency for Drugs and Technologies in Health, January 2021

CADTH common drug review

Version: Final (with redactions).

4

Pharmacoeconomic review report : indication : for the maintenance treatment of steroid-responsive bronchial asthma as prophylactic therapy in patients 12 years of age and olderFluticasone propionate (Aermony Respiclick) (Teva Canada Innovation)

Erschienen: Ottawa (ON), CADTH, January 2019

CADTH common drug review

Final (with redactions).

5

Pharmacoeconomic review report : indication : an add-on maintenance treatment of adult patients with severe eosinophilic asthmaBenralizumab (Fasenra) (AstraZeneca Canada Inc.)

Erschienen: Ottawa (ON), CADTH, August 2018

CADTH common drug review

Final with redactions.

6

CADTH Canadian drug expert committee recommendation : indication : severe eosinophilic asthmaBenralizumab (Fasenra -- Astrazeneca Canada Inc.)

Erschienen: Ottawa (ON), CADTH, August 2018

CADTH common drug review

Final.

7

CADTH Canadian Drug Expert Committee recommendation : indication : maintenance treatment of asthma in patients 12 years of age and olderFluticasone Propionate (Aermony respiclick -- Teva Canada Innovation)

Erschienen: Ottawa (ON), CADTH, December 21, 2018

CADTH common drug review

Final.

8

Intermittent inhaled corticosteroids and long-acting muscarinic antagonists for asthma

Erschienen: Rockville, MD, Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, March 2018

Comparative effectiveness review - number 194

von Sobieraj, D.

9

Pharmacoeconomic review report : Omalizumab (Xolair)

Erschienen: Ottawa (ON), CADTH, September 2017

CADTH common drug review

10

Omalizumab (Xolair)

Erschienen: Ottawa (ON), CADTH, September 2017

Common drug review clinical review report

Filter & Sortierung